Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tetraxim + ActHIB
- Development stage
- Unknown
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Tetraxim + ActHIB is a combination vaccine regimen developed by Sanofi for the active immunization of infants and children against diphtheria, tetanus, pertussis, poliomyelitis, and invasive diseases caused by Haemophilus influenzae type b. Tetraxim is a quadrivalent vaccine containing diphtheria and tetanus toxoids, acellular pertussis antigens (pertussis toxoid and filamentous hemagglutinin), and inactivated poliovirus types 1, 2, and 3. ActHIB is a conjugate vaccine consisting of the Haemophilus influenzae type b capsular polysaccharide (PRP) coupled to tetanus protein. The two vaccines are typically administered together, either by using Tetraxim to reconstitute the lyophilized ActHIB or by simultaneous injection at separate sites. This combination provides a pentavalent immunization schedule to reduce the number of injections required for primary and booster series.
- Brand names
- ActHIB
- Other names
- DTacP-IPV + PRP-TDTaP-IPV + Hib
02
Targets
FHA (Filamentous hemagglutinin)Poliovirus type 3 virion structural antigensPoliovirus type 1 capsid proteinPRNP (Cellular Prion Protein)Diphtheria toxinPoliovirus type 2 capsid protein
Beyond the preview
Go deeper on Tetraxim + ActHIB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tetraxim + ActHIB.